Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.40M in total
- 10
- 13F holdersQ2 2026, +17 vs. previous quarter
- 211
- 13F valueReported value at the end of Q2 2026
- $2.84B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding NRIX, Q2 2026
1 superinvestor reports holding Nurix Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.3%
Nurix Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,793,196
- Value
- $43.5M
Latest insider trades
Open-market purchases and sales by Nurix Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)7:42 PM ET | Sep 2 | Same day | Ring ChristineChief Legal Officer | SSale | −5.79K | $25.76 | −$149.1K | −38.8%9.11K after | 2 lots10b5-1 |
| Sep 1, 2026 (view filing)5:19 PM ET | Sep 1 | Same day | Hansen GwennChief Scientific Officer | SSale | −1.45K | $25.47 | −$37.0K | −1.2%117.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)6:59 PM ET | Aug 5 | Same day | Hansen GwennChief Scientific Officer | SSale | −4.36K | $25.00 | −$108.9K | −3.6%117.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)6:39 AM ET | Aug 4 | 1 day | Hansen GwennChief Scientific Officer | SSale | −4.11K | $24.36 | −$100.1K | −3.4%117.2K after | 2 lots10b5-1 |
| Aug 4, 2026 (view filing)9:41 PM ET | Aug 4 | Same day | van Houte HansChief Financial Officer | SSale | −4.76K | $24.36 | −$116.0K | −10.6%40.2K after | 2 lots10b5-1 |
| Aug 3, 2026 (view filing)5:51 PM ET | Aug 3 | Same day | Ring ChristineChief Legal Officer | SSale | −16.6K | $23.05 | −$382.4K | −64.6%9.11K after | 10b5-1 |
| Jul 30, 2026 (view filing)5:58 PM ET | Jul 30 | Same day | van Houte HansChief Financial Officer | SSale | −2.85K | $23.38 | −$66.5K | −6.0%44.9K after | |
| Jul 30, 2026 (view filing)5:56 PM ET | Jul 30 | Same day | Ring ChristineChief Legal Officer | SSale | −3.85K | $23.38 | −$90.0K | −16.2%19.9K after | |
| Jul 30, 2026 (view filing)5:50 PM ET | Jul 30 | Same day | Hansen GwennChief Scientific Officer | SSale | −3.85K | $23.38 | −$90.0K | −3.1%121.3K after | |
| Jul 2, 2026 (view filing)6:02 PM ET | Jul 2 | Same day | Ring ChristineChief Legal Officer | SSale | −11.0K | $23.56 | −$259.4K | −44.8%13.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nurix Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,770,349 | $212.8M | 0.00% | −155,293−1.7% | Reduced |
| Vestal Point Capital, LP | 8,050,000 | $195.3M | 4.56% | +1,550,000+23.8% | Added |
| Deep Track Capital, LP | 7,736,455 | $187.7M | 2.76% | +1,391,211+21.9% | Added |
| Rubric Capital Management LP | 7,227,778 | $175.3M | 1.61% | +4,753,893+192.2% | Added |
| FMR LLC | 5,485,215 | $133.1M | 0.01% | −56,056−1.0% | Reduced |
| Price T Rowe Associates Inc | 5,436,587 | $131.9M | 0.01% | +2,146,354+65.2% | Added |
| Morgan Stanley | 4,762,484 | $115.5M | 0.01% | −169,515−3.4% | Reduced |
| State Street Corp | 4,677,244 | $113.5M | 0.00% | −463,951−9.0% | Reduced |
| Baker Bros. Advisors LP | 4,658,556 | $113.0M | 0.57% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,495,529 | $109.1M | 0.00% | +68,417+1.5% | Added |